THE 'ENHANCER' SNP DOES NOT EXPLAIN VARIABILITY OF CYP2D6 ACTIVITY IN VIVO.

被引：0
|
作者：
Boone, E. C. [1 ]
Staggs, V. T. [1 ]
Pearce, R. E. [1 ]
Lata, R. F. [1 ]
Gaedigk, R. [1 ]
Jaime, L. K. Montane [2 ]
Cherner, M. [3 ]
Berard, A. [4 ]
Fridley, B. L. [5 ]
Dinh, J. C. [1 ]
Miller, N. A. [1 ]
Leeder, J. [1 ]
Gaedigk, A. [1 ]
机构：
[1] Childrens Mercy Kansas City, Kansas City, MO USA
[2] Int Inst Hlth Care Profess, Boca Raton, FL USA
[3] Univ Calif San Diego, San Diego, CA 92103 USA
[4] Univ Montreal, Montreal, PQ, Canada
[5] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2019年 / 105卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PII-055
引用
收藏
页码：S57 / S57
页数：1
相关论文
共 50 条
  • [31] CYP2D6 expression is regulated by polymorphisms that affect splicing and trancription: new biomarkers for CYP2D6 activity
    Wang, Danxin
    Poi, Ming J.
    Sun, Xiaochun
    Gaedigk, Andrea
    Leeder, J. Steven
    Sadee, Wolfgang
    FASEB JOURNAL, 2013, 27
  • [32] Impact of CYP2D6*2, CYP2D6*35, rs5758550, and related haplotypes on risperidone clearance in vivo
    Storset, Elisabet
    Braten, Line Skute
    Ingelman-Sundberg, Magnus
    Johansson, Inger
    Molden, Espen
    Kringen, Marianne Kristiansen
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2024, 80 (10) : 1531 - 1541
  • [33] Duplication of CYP2D6 predicts high clearance of desipramine but high clearance does not predict duplication of CYP2D6
    Bergmann, TK
    Bathum, L
    Brosen, K
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 57 (02) : 123 - 127
  • [34] Common mutant alleles of CYP2D6 causing the defect of CYP2D6 enzyme activity in a Japanese population
    Ishiguro, A
    Kubota, T
    Sasaki, H
    Yamada, Y
    Iga, T
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 55 (04) : 414 - U3
  • [35] A novel CYP2D6 scoring system for the prediction of CYP2D6 activity: Application to tamoxifen metabolism.
    Borges, S.
    Li, L.
    Robarge, J.
    Nguyen, A.
    Azzouz, F.
    Desta, Z.
    Skaar, T.
    Flockhart, D. A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 : S67 - S67
  • [36] In vivo inhibition of CYP2C19 but not CYP2D6 by fluvoxamine
    Xu, ZH
    Xie, HG
    Zhou, HH
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1996, 42 (04) : 518 - 521
  • [37] The Effects of Puerarin on CYP2D6 and CYP1A2 Activities In Vivo
    Zheng, Jiao
    Chen, Bin
    Jiang, Bing
    Zeng, Ling
    Tang, Zhi-Rong
    Fan, Lan
    Zhou, Hong-Hao
    ARCHIVES OF PHARMACAL RESEARCH, 2010, 33 (02) : 243 - 246
  • [38] The effects of Puerarin on CYP2D6 and CYP1A2 activities In vivo
    Jiao Zheng
    Bin Chen
    Bing Jiang
    Ling Zeng
    Zhi-Rong Tang
    Lan Fan
    Hong-Hao Zhou
    Archives of Pharmacal Research, 2010, 33 : 243 - 246
  • [39] NEW aQTL SNPs FOR THE CYP2D6 IDENTIFIED BY A NOVEL MEDIATION ANALYSIS OF GENOME-WIDE SNP ARRAYS, GENE EXPRESSION ARRAYS, AND CYP2D6 ACTIVITY.
    Jiang, G.
    Zhang, B.
    Desta, Z.
    Liu, Y.
    Gaedigk, A.
    Skaar, T.
    Li, L.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 91 : S117 - S118
  • [40] GENETIC POLYMORPHISM IN CYTOCHROME P450 2D6 (CYP2D6): POPULATION DISTRIBUTION OF CYP2D6 ACTIVITY
    Neafsey, Patricia
    Ginsberg, Gary
    Hattis, Dale
    Sonawane, Babasaheb
    JOURNAL OF TOXICOLOGY AND ENVIRONMENTAL HEALTH-PART B-CRITICAL REVIEWS, 2009, 12 (5-6): : 334 - 361
12345